{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:51Z","timestamp":1791300531979,"version":"4.1.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T00:00:00Z","timestamp":1256860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10,30]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>The clinical use of intravenous immunoglobulin (IVIg) has expanded beyond its traditional place in the treatment of patients with primary immunodeficiencies. Due to its multiple anti-inflammatory and immunomodulatory properties, IVIg is used successfully in a wide range of autoimmune and inflammatory conditions. Recognized autoimmune indications include idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain\u2013Barr\u00e9 syndrome and other autoimmune neuropathies, myasthenia gravis, dermatomyositis and several rare diseases. Several other indications are currently under investigation and require additional studies to establish firmly the benefit of IVIg treatment. Increasing attention is being turned to the use of IVIg in combination with other agents, such as immunosuppressive agents or monoclonal antibodies. For example, recent studies suggest that combination therapy with IVIg and rituximab (an anti-CD20 monoclonal antibody) may be effective for treatment of autoimmune mucocutaneous blistering diseases (AMBDs), with sustained clinical remission. The combination of IVIg and rituximab has also been used in the setting of organ transplantation. Firstly, IVIg\u2003\u00b1\u2003rituximab has been administered to highly human leucocyte antigen (HLA)-sensitized patients to reduce anti-HLA antibody levels, thereby allowing transplantation in these patients. Secondly, IVIg in combination with rituximab is effective in the treatment of antibody-mediated rejection following transplantation. Treatment with polyclonal IVIg is a promising adjunctive therapy for severe sepsis and septic shock, but its use remains controversial and further study is needed before it can be recommended routinely. This review covers new developments in these fields and highlights the broad range of potential therapeutic areas in which IVIg may have a clinical impact.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2009.04024.x","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T18:33:24Z","timestamp":1256927604000},"page":"23-33","source":"Crossref","is-referenced-by-count":111,"title":["Clinical applications of intravenous immunoglobulins (IVIg) \u2013 beyond immunodeficiencies and neurology"],"prefix":"10.1093","volume":"158","author":[{"given":"H-P","family":"Hartung","sequence":"first","affiliation":[{"name":"Department of Neurology, Heinrich-Heine University, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Mouthon","sequence":"additional","affiliation":[{"name":"Cochin Hospital and Paris-Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Center for Blistering Disease, New England Baptist Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jordan","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K B","family":"Laupland","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Critical Care Medicine, Pathology and Laboratory Medicine, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jolles","sequence":"additional","affiliation":[{"name":"University Hospital of Wales, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,10,30]]},"reference":[{"key":"2021122708525338400_b1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"2021122708525338400_b2","doi-asserted-by":"crossref","first-page":"85S","DOI":"10.1592\/phco.2005.25.11part2.85S","article-title":"The patient: emerging clinical applications of intravenous immunoglobulin","volume":"25","author":"Harvey","year":"2005","journal-title":"Pharmacotherapy"},{"key":"2021122708525338400_b3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0755-4982(06)74668-1","article-title":"Indications for intravenous immunoglobulins","volume":"35","author":"Mouthon","year":"2006","journal-title":"Presse Med"},{"key":"2021122708525338400_b4","volume-title":"Clinical guidelines for immunoglobulin use","author":"UK Department of Health","edition":"2nd"},{"key":"2021122708525338400_b5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2310\/7750.2006.00048","article-title":"Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology","volume":"10","author":"Mydlarski","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"2021122708525338400_b6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.tmrv.2007.01.004","article-title":"Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions","volume":"21","author":"Robinson","year":"2007","journal-title":"Transfus Med Rev"},{"key":"2021122708525338400_b7","volume-title":"Criteria for the clinical use of intravenous immunoglobulin in Australia","author":"Australian Health Ministers' Conference"},{"key":"2021122708525338400_b8","first-page":"CD004000","article-title":"Intravenous immunoglobulin for the treatment of Kawasaki disease in children","author":"Oates-Whitehead","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122708525338400_b9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(83)91109-1","article-title":"High-dose intravenous gammaglobulin for Kawasaki disease","volume":"2","author":"Furusho","year":"1983","journal-title":"Lancet"},{"key":"2021122708525338400_b10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0140-6736(84)91504-6","article-title":"High-dose intravenous gammaglobulin for Kawasaki disease","volume":"2","author":"Furusho","year":"1984","journal-title":"Lancet"},{"key":"2021122708525338400_b11","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000145143.19711.78","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association","volume":"110","author":"Newburger","year":"2004","journal-title":"Circulation"},{"key":"2021122708525338400_b12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(85)91147-X","article-title":"Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis","volume":"1","author":"Van der Woude","year":"1985","journal-title":"Lancet"},{"key":"2021122708525338400_b13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0140-6736(91)92797-6","article-title":"Treatment of systemic vasculitis with pooled intravenous immunoglobulin","volume":"337","author":"Jayne","year":"1991","journal-title":"Lancet"},{"key":"2021122708525338400_b14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/978-1-4757-9182-2_84","article-title":"Pooled intravenous immunoglobulin in the management of systemic vasculitis","volume":"336","author":"Jayne","year":"1993","journal-title":"Adv Exp Med Biol"},{"key":"2021122708525338400_b15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.1995.tb02268.x","article-title":"Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin","volume":"101","author":"Richter","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2021122708525338400_b16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000024199","article-title":"Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin","volume":"119","author":"Levy","year":"1999","journal-title":"Int Arch Allergy Immunol"},{"key":"2021122708525338400_b17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Q J Med"},{"key":"2021122708525338400_b18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients","volume":"58","author":"Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021122708525338400_b19","first-page":"391","article-title":"Drug therapy of pemphigus vulgaris","volume":"142","author":"Ahmed","year":"2007","journal-title":"G Ital Dermatol Venereol"},{"key":"2021122708525338400_b20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archderm.139.8.1051","article-title":"Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases","volume":"139","author":"Ahmed","year":"2003","journal-title":"Arch Dermatol"},{"key":"2021122708525338400_b21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.intimp.2005.11.018","article-title":"Use of intravenous immunoglobulin therapy in autoimmune blistering diseases","volume":"6","author":"Ahmed","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"2021122708525338400_b22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.intimp.2005.11.002","article-title":"Comparison of the cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases","volume":"6","author":"Daoud","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"2021122708525338400_b23","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1034\/j.1600-6143.2003.00121.x","article-title":"Utility of intravenous immune globulin in kidney transplantation: efficacy, safety and cost implications","volume":"3","author":"Jordan","year":"2003","journal-title":"Am J Transplant"},{"key":"2021122708525338400_b25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM196904032801401","article-title":"Significance of the positive crossmatch test in kidney transplantation","volume":"280","author":"Patel","year":"1969","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b26","first-page":"201","article-title":"Anti-HLA class II antibodies and chronic allograft nephropathy","author":"Gerbase-DeLima","year":"2006","journal-title":"Clin Transpl"},{"key":"2021122708525338400_b27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2215\/CJN.01651105","article-title":"Presensitization: the problem and its management","volume":"1","author":"Jordan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021122708525338400_b28","first-page":"199","article-title":"Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation","volume":"117","author":"Jordan","year":"2006","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"2021122708525338400_b29","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly-HLA sensitized adult patients with end stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2021122708525338400_b30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.humimm.2005.01.032","article-title":"Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin","volume":"66","author":"Zachary","year":"2005","journal-title":"Hum Immunol"},{"key":"2021122708525338400_b31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/TP.0b013e3181856f98","article-title":"Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy","volume":"86","author":"Reinsmoen","year":"2008","journal-title":"Transplantation"},{"key":"2021122708525338400_b32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.TP.0000112934.12622.2B","article-title":"Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: safety, pharmocodynamics and pharmacokinetics","volume":"77","author":"Vieira","year":"2004","journal-title":"Transplantation"},{"key":"2021122708525338400_b33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":"Rituximab therapy for acute humoral rejection after kidney transplantation","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"key":"2021122708525338400_b34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ncpneph0133","article-title":"Drug insight: rituximab in renal disease in transplantation","volume":"2","author":"Salama","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"2021122708525338400_b35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00003246-199206000-00025","article-title":"American College of Chest Physicians\/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"20","year":"1992","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b37","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b38","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1213\/ane.0b013e318187bbd8","article-title":"The impact of severe sepsis on health-related quality of life: a long-term follow-up study","volume":"107","author":"Hofhuis","year":"2008","journal-title":"Anesth Analg"},{"key":"2021122708525338400_b39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00134-004-2544-6","article-title":"One-year mortality of bloodstream infection-associated sepsis and septic shock among patients presenting to a regional critical care system","volume":"31","author":"Laupland","year":"2005","journal-title":"Intens Care Med"},{"key":"2021122708525338400_b40","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00134-004-2157-0","article-title":"Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units","volume":"30","author":"Finfer","year":"2004","journal-title":"Intens Care Med"},{"key":"2021122708525338400_b42","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1097\/01.CCM.0000085141.75513.2B","article-title":"Epidemiology of severe sepsis occurring in the first 24\u2003hrs in intensive care units in England, Wales, and Northern Ireland","volume":"31","author":"Padkin","year":"2003","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b43","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s00134-006-0517-7","article-title":"Epidemiology of sepsis in Germany: results from a national prospective multicenter study","volume":"33","author":"Engel","year":"2007","journal-title":"Intens Care Med"},{"key":"2021122708525338400_b44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00134-003-2136-x","article-title":"EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units","volume":"30","author":"Brun-Buisson","year":"2004","journal-title":"Intens Care Med"},{"key":"2021122708525338400_b45","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1097\/01.CCM.0000284492.30800.00","article-title":"Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China","volume":"35","author":"Cheng","year":"2007","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","article-title":"Sepsis in European intensive care units: results of the SOAP study","volume":"34","author":"Vincent","year":"2006","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b47","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1056\/NEJM199703273361303","article-title":"The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group","volume":"336","author":"Bernard","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM198709103171102","article-title":"Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis","volume":"317","author":"The Veterans Administration Systemic Sepsis Cooperative Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJM198709103171101","article-title":"A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock","volume":"317","author":"Bone","year":"1987","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b50","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.283.13.1723","article-title":"E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators","volume":"283","author":"Angus","year":"2000","journal-title":"JAMA"},{"key":"2021122708525338400_b51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"key":"2021122708525338400_b52","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa011300","article-title":"Intensive insulin therapy in the critically ill patients","volume":"345","author":"Van Den Berghe","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b53","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b54","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jama.288.7.862","article-title":"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock","volume":"288","author":"Annane","year":"2002","journal-title":"JAMA"},{"key":"2021122708525338400_b55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa010877","article-title":"Daily hemodialysis and the outcome of acute renal failure","volume":"346","author":"Schiffl","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b56","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMoa010307","article-title":"Early goal-directed therapy in the treatment of severe sepsis and septic shock","volume":"345","author":"Rivers","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b57","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/01.CCM.0000117317.18092.E4","article-title":"Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock","volume":"32","author":"Dellinger","year":"2004","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(08)70306-2","article-title":"Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis","volume":"9","author":"Poole","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2021122708525338400_b59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa071366","article-title":"Hydrocortisone therapy for patients with septic shock","volume":"358","author":"Sprung","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMoa0802639","article-title":"Intensity of renal support in critically ill patients with acute kidney injury","volume":"359","author":"Palevsky","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b61","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008","volume":"36","author":"Dellinger","year":"2008","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b63","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3201\/eid0203.960306","article-title":"Antibody-based therapies for emerging infectious diseases","volume":"2","author":"Casadevall","year":"1996","journal-title":"Emerg Infect Dis"},{"key":"2021122708525338400_b64","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","article-title":"Serum therapy revisited: animal models of infection and development of passive antibody therapy","volume":"38","author":"Casadevall","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2021122708525338400_b65","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2796.2006.01726.x","article-title":"Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis","volume":"260","author":"Norrby-Teglund","year":"2006","journal-title":"J Intern Med"},{"key":"2021122708525338400_b66","first-page":"CD001090","article-title":"Intravenous immunoglobulin for treating sepsis and septic shock","volume":"1","author":"Alejandria","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122708525338400_b67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1086\/421089","article-title":"Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review","volume":"39","author":"Pildal","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021122708525338400_b68","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcrc.2005.03.003","article-title":"Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock","volume":"20","author":"Neilson","year":"2005","journal-title":"J Crit Care"},{"key":"2021122708525338400_b69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7326\/0003-4819-146-3-200702060-00009","article-title":"Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis","volume":"146","author":"Turgeon","year":"2007","journal-title":"Ann Intern Med"},{"key":"2021122708525338400_b70","first-page":"2686","article-title":"Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis","volume":"35","author":"Laupland","year":"2007","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b71","first-page":"2677","article-title":"Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock","volume":"35","author":"Kreymann","year":"2007","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b72","first-page":"2693","article-title":"Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study","volume":"35","author":"Werdan","year":"2007","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b73","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.CCM.0000215452.84291.C6","article-title":"IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial","volume":"34","author":"Hentrich","year":"2006","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b74","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1097\/00003246-200712000-00026","article-title":"Mirror, mirror on the wall, which is the fairest meta-analysis of all?","volume":"35","author":"Werdan","year":"2007","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b75","first-page":"2855","article-title":"To use or not to use? Polyclonal intravenous immunoglobulins for the treatment of sepsis and septic shock","volume":"35","author":"Neugebauer","year":"2007","journal-title":"Crit Care Med"},{"key":"2021122708525338400_b76","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1600-6143.2008.02173.x","article-title":"Kidney and pancreas transplantation in the United States, 1997\u20132006: the HRSA Breakthrough Collaboratives and the 58 DSA Challenge","volume":"8","author":"Leichtman","year":"2008","journal-title":"Am J Transplant"},{"key":"2021122708525338400_b77","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa040232","article-title":"A comparison of albumin and saline for fluid resuscitation in the intensive care unit","volume":"350","author":"Finfer","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122708525338400_b78","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1378\/chest.111.2.419","article-title":"Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis","volume":"111","author":"Pilz","year":"1997","journal-title":"Chest"},{"key":"2021122708525338400_b79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcrc.2004.04.001","article-title":"Intravenous immunoglobulin for severe infections: a survey of Canadian specialists","volume":"19","author":"Laupland","year":"2004","journal-title":"J Crit Care"},{"key":"2021122708525338400_b80","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/00365540600786499","article-title":"A survey of physician's attitudes regarding management of severe group A streptococcal infections","volume":"38","author":"Valiquette","year":"2006","journal-title":"Scand J Infect Dis"},{"key":"2021122708525338400_b81","first-page":"CD001239","article-title":"Intravenous immunoglobulin for suspected or subsequently proven infection in neonates","volume":"1","author":"Ohlsson","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122708525338400_b82","volume-title":"INIS: International Neonatal Immunotherapy Study","author":"National Perinatal Epidemiology Unit (NPEU)"},{"key":"2021122708525338400_b83","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/rheumatology\/35.11.1150","article-title":"Intravenous immunoglobulin as sole therapy for systemic vasculitis","volume":"35","author":"Jayne","year":"1996","journal-title":"Br J Rheumatol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2009.04024.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/158\/Supplement_1\/23\/41925468\/j.1365-2249.2009.04024.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/158\/Supplement_1\/23\/41925468\/j.1365-2249.2009.04024.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:21:59Z","timestamp":1641054119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/158\/Supplement_1\/23\/6428817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,30]]},"references-count":83,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2009,10,30]]},"published-print":{"date-parts":[[2009,10,30]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2009.04024.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,12]]},"published":{"date-parts":[[2009,10,30]]}}}